Related Experiment Video
Updated: Mar 28, 2026
Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
[R ± BEACOP for Treating Newly Diagnosed, Moderate and High Risk Diffuse Large B Cell Lymphoma Patients]
Fei Dong1, Jing Wang1, Ping Yand1
1Department of Hematology, Peking University Third hospital, Beijing 100191, China.
Objective:
To evaluate the efficacy and safety of R ± BEACOP protocol on newly diagnosed patients with moderate and high risk diffuse large B-cell lymphoma (DLBCL).
Methods:
The clinical data of 19 newly diagnosed patients with moderate and high risk DLBCL received at least 2 cycles of R ± BEACOP protocol during 2011 to 2014 were collected, their therapeutic efficacy and side effects were evaluated by retrospective analysis.
Results:
The overall response rate of 19 assessable patients was 94.7%, including 5 patients (26.3%) in complete remission (CR) and 13 patients (68.4%) in partial remission (PR). The major toxicity was hematologic toxicity and the incidence of grade III-IV hematologic toxicity was 73.7%. Other toxicities were mild and no treatment-related death occurred.
Conclusion:
R ± BEACOP protocol is a effective and safe protocol for the patients with DLBCL which is worth further multicenter prospectively studying in china.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
06:51Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers